In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy. NLM AIDSLINE Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy.

J Antimicrob Chemother. 2000 Feb;45(2):239-42. Unique Identifier : AIDSLINE MED/20127829
Rodero L; Cordoba S; Cahn P; Hochenfellner F; Davel G; Canteros C; Kaufman S; Guelfand L; Departamento Micologia, Instituto Nacional de Enfermedades; Infecciosas, ANLIS 'Dr Carlos G. Malbran', Av. Velez Sarsfield; 563, 1281 Buenos Aires, Argentina. lrodero@mail.retina.ar

Abstract: The in vitro activities of three antifungal drugs alone and in combination were evaluated against five isolates of Cryptococcus neoformans using time-kill curves (TKC). The isolates were from AIDS patients who had either died or had failed to show a clinical response during amphotericin B (AMB) treatment. AMB, fluconazole (FCZ) and flucytosine (5FC), and combinations of the drugs (AMB plus 5FC, AMB plus rifampicin (RIF) and FCZ plus 5FC), were evaluated. With all five isolates AMB did not show fungicidal activity; instead, a persistent or tolerant effect was observed. Combinations of AMB plus 5FC and AMB plus RIF showed a clear synergic effect, except for one isolate tested with AMB plus RIF. In contrast, the FCZ plus 5FC combination did not inhibit growth of any isolate.

Keywords: JOURNAL ARTICLE Acquired Immunodeficiency Syndrome/MICROBIOLOGY Amphotericin B/*PHARMACOLOGY/*THERAPEUTIC USE Antibiotics, Antifungal/*PHARMACOLOGY/*THERAPEUTIC USE Cryptococcosis/*MICROBIOLOGY Cryptococcus neoformans/*DRUG EFFECTS Drug Interactions Drug Resistance, Microbial Fluconazole/PHARMACOLOGY Flucytosine/PHARMACOLOGY Human Leprostatic Agents/PHARMACOLOGY Rifampin/PHARMACOLOGY Time Factors

KWDjournalarticleacquiredimmunodeficiencysyndrome/microbiologyamphotericinb/KWDpharmacology/KWDtherapeuticuseantibiotics,antifungal/KWDpharmacology/KWDtherapeuticusecryptococcosis/KWDmicrobiologycryptococcusneoformans/KWDdrugeffectsdruginteractionsdrugresistance,microbialfluconazole/pharmacologyflucytosine/pharmacologyhumanleprostaticagents/pharmacologyrifampin/pharmacologytimefactors
000630
A0061932

Copyright © 2000 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .